Most hepatocellular carcinoma (HCC) patients worldwide do not receive curative treatments. Alternative treatments for most HCC patients include palliative treatments, such as transarterial chemoembolization (TACE), chemotherapy, and radiotherapy. Although statins may be a chemopreventive treatment option for reducing hepatitis B virus (HBV)-and hepatitis C virus (HCV)-related HCC risks, their therapeutic effects are unknown. This study evaluated the effects of statin on HCC patients receiving palliative treatment. Data from the National Health Insurance claims database and cancer registry databases of The Collaboration Center of Health Information Application, Taiwan, were analyzed. We included HCC patients who were treated between January 1, 2001, and December 31, 2010, and followed them from the index date to December 31, 2012. The inclusion criteria were presence of HBV carrier-related HCC, age

Original languageEnglish
Pages (from-to)e1801
JournalMedicine (United States)
Issue number42
Publication statusPublished - Oct 1 2015

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Statin-based palliative therapy for hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this